On March 18, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported upcoming presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting and NextGen Biomed 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) Annual Meeting will take place April 17–22, 2026 in San Diego, California, and NextGen Biomed 2026 will be held March 24–26, 2026 in London, United Kingdom.

Presentation Details:

AACR Poster Session (abi-suva)
Session title: Phase I Clinical Trials
Title: Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: preliminary results from phase 1 of the VB-C-03 trial

Location: Poster Section 50
Poster Board Number: 9
Date: April 21, 2026
Time: 09:00 AM – 12:00 PM PDT

NextGen Biomed Presentation (VB10.NEO)
Title: VB10.NEO: The Journey of a Clinically Validated Individualized Cancer Therapy from Tumour Biopsy to Vaccine Administration

Date: March 24, 2026
Time: 11:40-12:00 GMT

NextGen Biomed Presentation (Tolerance):
Title: Development Of APC-Targeted Antigen-Specific Immune Tolerance Therapies For Autoimmune Diseases

Date: March 25, 2026
Time: 12:00-12:25 GMT

The presentation slides will be available after the presentations at the
Company’s webpage:
View Source

(Press release, Nykode Therapeutics, MAR 18, 2026, View Source [SID1234663704])